Purpose: Management of chronic vision threatening auto-immune ocular diseases (AIOD, e.g. uveitis, scleritis) can be challenging. Guidelines recommend a multidisciplinary approach (MDA) with ophthalmologists and rheumatologists, to enhance the recognition of systemic diseases and guide the use of immunosuppressives. However, the indications and results of such an approach have not yet been studied.
Methods: A monocentre, retrospective chart review of all patients treated in a MDA between ophthalmologists and rheumatologists, in a Dutch tertiary center. The collaboration was twofold: a combined multidisciplinary team meeting every 2 weeks, and an ophthalmology-dedicated rheumatology outpatient clinic. Primary endpoints of this descriptive study were as follows: indications for MDA, new diagnoses of systemic auto-immune diseases and changes in systemic immunosuppression and prednisone dosages.
Results: In total, 157 adults (mean age 46 years, 57% female, median disease duration 19 months) were included, mainly with uveitis (74%) and scleritis (12%). Multidisciplinary approach (MDA)-indications included diagnostic workup (32%), treatment support (44%), diagnostic-and-treatment support (10%) and side effects (8%). A systemic disease was newly diagnosed in eight and already present in 34 patients. At baseline, 54 patients used oral prednisone at >7.5 mg/day. Non-corticoid immunosuppressives, mostly methotrexate, were started in 41% of the patients. During follow-up, systemic prednisone was lowered to ≤7.5 mg/day in 68% of the patients.
Conclusion: This evaluation of an MDA-programme in the management of AIOD demonstrated its added value. Mainly, it addressed the high demand for support in managing systemic immunosuppression, resulting in significant corticosteroid tapering. In addition, it resulted in the recognition of underlying systemic diseases.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984222 | PMC |
http://dx.doi.org/10.1111/aos.14548 | DOI Listing |
Nat Rev Rheumatol
December 2024
Department of Paediatric Rheumatology, Bristol Royal Hospital for Children, Bristol, UK.
Clin Rheumatol
December 2024
Division of Rheumatology, Department of Medicine, University of Washington, 1959 NE Pacific St Health Sciences Bldg BB561 Campus Box 356428, Seattle, WA, 98195, USA.
Objective: Giant cell arteritis (GCA) is the most common vasculitis and can result in blindness due to anterior ischemic optic neuropathy (AION). Little is known about which patients with GCA are at higher risk of AION. We did a retrospective chart review to compare demographics, past medical history, labs and imaging of GCA patients with and without AION.
View Article and Find Full Text PDFRheumatology (Oxford)
September 2024
Department of Diagnostic and Interventional Radiology, University Hospital Wuerzburg, Wuerzburg, Germany.
Objectives: There are an increasing number of centers performing research on high-resolution vessel wall magnetic resonance imaging (VW-MRI) in giant cell arteritis (GCA). However, harmonized approaches to VW-MRI in GCA are lacking and are essential to performing multicentre studies. Using a data-driven, consensus-based approach, an international expert group developed a standardized MRI protocol and scoring system to advance multi-centered research in cranial GCA.
View Article and Find Full Text PDFCureus
August 2024
Rheumatology, First Person Care Clinic, Las Vegas, USA.
Tubulointerstitial nephritis and uveitis (TINU) syndrome is an uncommon autoimmune disorder that is defined by tubulointerstitial nephritis and uveitis. It is frequently underdiagnosed or goes unrecognized due to the challenges of accurately diagnosing the syndrome. TINU has mostly been seen among female pediatric patients with primarily bilateral anterior uveitis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!